文献速递银屑病与炎症性皮肤病

阿达木单抗治疗甲银屑病52周疗效与安全性:3期随机对照试验

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-09-04

这项3期随机对照试验评估阿达木单抗治疗中重度斑块状银屑病合并中重度指甲银屑病的长期疗效与安全性。217例患者随机进入双盲期,188例进入开放标签延展期;持续阿达木单抗组第52周mNAPSI 75达标率47.4-54.5%,PGA-F 0/1为51.1-55.6%,全部阿达木单抗组严重不良事件率6.9%、严重感染率3.4%。

要点

  • 阿达木单抗每两周40mg可改善甲银屑病,52周时mNAPSI 75达标率约半数。
  • 持续治疗至52周,甲损害完全清除率从6.6%升至17.9%。
  • 全部阿达木单抗组严重不良事件率6.9%,严重感染率3.4%。

核心结论

  • 在中重度斑块状银屑病合并中重度指甲银屑病患者中,阿达木单抗每两周40mg治疗52周显示长期疗效,甲病体征和症状改善,包括甲病完全清除率的递增改善。
  • 接受至少一剂阿达木单抗治疗52周的患者未发现新的安全性风险。

研究设计与样本

  • 3期随机安慰剂对照试验,双盲期(A期)26周后进入26周开放标签延展期(OLE)。
  • A期随机217例患者,188例(86.6%,每组94例)完成或提前退出后进入OLE。
  • 持续阿达木单抗组(Continuous-ADA Population)N=109;全部阿达木单抗组(All-ADA Population)N=203。

主要发现

  • 持续阿达木单抗组从OLE入口(第26周)至第52周,全指甲mNAPSI 75达标率从47.4%升至54.5%。
  • 持续阿达木单抗组PGA-F 0/1(较基线改善≥2级)达标率从51.1%升至55.6%。
  • 持续阿达木单抗组全指甲mNAPSI=0率从6.6%升至17.9%。
  • 全部阿达木单抗组严重不良事件率6.9%,严重感染率3.4%。

关键数值与推荐

  • 主要疗效评估:全指甲改良甲银屑病严重指数改善≥75%(mNAPSI 75)。
  • 主要疗效评估:指甲银屑病医师全局评估达清除或轻微(PGA-F 0/1)且较基线改善≥2级。
  • 给药方案:阿达木单抗40mg每两周一次。

临床怎么用

  • 对于中重度斑块状银屑病合并中重度指甲银屑病患者,可考虑阿达木单抗每两周40mg长期治疗以改善甲损害。
  • 治疗52周可持续改善甲银屑病,部分患者可达甲病完全清除。
  • 长期治疗安全性与该药已知安全性一致,未发现新风险。

局限性

  • OLE期为开放标签设计,无安慰剂对照。
  • 持续阿达木单抗组样本量有限(N=109)。
  • 原文未报告其他长期对照数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few clinical trials have evaluated long-term treatment of nail psoriasis with biologics. OBJECTIVE: Safety and efficacy of adalimumab [ADA; Humira AbbVie Inc, North Chicago, IL, USA)] long-term treatment (52 weeks) was evaluated in a phase-3, randomized trial in patients with moderate-to-severe plaque psoriasis and concomitant moderate-to-severe fingernail psoriasis. Results from the first 26 weeks (Period A) have been reported. METHODS: Patients receiving 40 mg ADA every other week or placebo in Period A, continued with or switched to 40 mg ADA every-other-week treatment in the subsequent 26-week open-label extension (OLE) period. Main efficacy evaluations were ≥75% improvement in total-fingernail modified Nail Psoriasis Severity Index (mNAPSI 75) and achievement of Physician's Global Assessment for Fingernail Psoriasis of clear or minimal disease (PGA-F 0/1) with a ≥2-grade improvement from baseline, across the trial for patients who continued ADA from Period A through the OLE (Continuous-ADA Population). Safety was evaluated during the OLE and for patients receiving ADA at any time during the study (All-ADA Population). RESULTS: Of the 217 patients initially randomized in Period A, 188 (86.6%; 94 in each treatment group) entered the OLE after completion of or early escape from Period A. For the Continuous-ADA Population (N = 109), endpoint achievement rates improved from OLE entry (Week 26) to Week 52, including total-fingernail mNAPSI 75 (47.4-54.5%); PGA-F 0/1 (51.1-55.6%) and total-fingernail mNAPSI = 0 (6.6-17.9%). Serious adverse event and serious infection rates for the All-ADA Population (N = 203) were 6.9% and 3.4%, respectively. CONCLUSIONS: In this population of psoriasis patients with concomitant, moderate-to-severe nail psoriasis, long-term efficacy and improvement in signs and symptoms of nail disease were demonstrated after every-other-week ADA treatment, including incremental improvements in rate of total clearance of nail disease. No new safety risks were identified for patients receiving at least one ADA dose across 52 weeks.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2019. PMID: 31304993. doi:10.1111/jdv.15793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。